Fate Therapeutics Inc (NASDAQ:FATE) shares were down 8.8% during trading on Wednesday . The company traded as low as $8.03 and last traded at $8.32. Approximately 679,347 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 648,247 shares. The stock had previously closed at $9.12.
A number of research analysts recently commented on FATE shares. ValuEngine raised shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Zacks Investment Research raised shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a report on Tuesday, January 9th. Raymond James Financial reaffirmed a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, December 12th. BMO Capital Markets reaffirmed a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Thursday, November 2nd. Finally, Piper Jaffray Companies started coverage on shares of Fate Therapeutics in a report on Monday, December 18th. They issued an “overweight” rating and a $10.00 price target for the company. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. Fate Therapeutics currently has an average rating of “Buy” and a consensus price target of $7.71.
The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21. The stock has a market capitalization of $424.17, a price-to-earnings ratio of -8.76 and a beta of 1.52.
A number of hedge funds and other institutional investors have recently made changes to their positions in FATE. New York State Common Retirement Fund bought a new stake in Fate Therapeutics in the second quarter worth about $131,000. Rhumbline Advisers bought a new stake in Fate Therapeutics in the second quarter worth about $133,000. Hochman Cole Investment Advisors Inc. bought a new stake in Fate Therapeutics in the third quarter worth about $158,000. Schwab Charles Investment Management Inc. bought a new stake in Fate Therapeutics in the second quarter worth about $214,000. Finally, California State Teachers Retirement System bought a new stake in Fate Therapeutics in the second quarter worth about $219,000. 49.86% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was posted by BBNS and is owned by of BBNS. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/markets/fate-therapeutics-fate-trading-down-8-8/1863842.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.